MAPT and neurodegenerative disease: CSF α-synuclein has been assessed as a biomarker in PD and other neurodegenerative diseases [66, 171, 253] and is a major focus area (together with tau and Aβ) of the Parkinson’s Progression Marker Initiative (PPMI) [168, 169].